相似文献
1
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest. 2013 May;143(5):1478-1479. doi: 10.1378/chest.12-1604.
2
Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.
BMC Infect Dis. 2021 Jan 7;21(1):27. doi: 10.1186/s12879-020-05703-2.
3
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81.
4
Ruxolitinib for myelofibrosis.
N Engl J Med. 2012 May 24;366(21):2032; author reply 2032-5. doi: 10.1056/NEJMc1203704.
5
Ruxolitinib for myelofibrosis.
N Engl J Med. 2012 May 24;366(21):2031; author reply 2032-4. doi: 10.1056/NEJMc1203704.
6
Ruxolitinib for myelofibrosis.
N Engl J Med. 2012 May 24;366(21):2031-2; author reply 2032-4. doi: 10.1056/NEJMc1203704.
7
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
8
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Postgrad Med. 2013 Jan;125(1):128-35. doi: 10.3810/pgm.2013.01.2628.
9
Ruxolitinib.
Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16.
10
Ruxolitinib: a review of its use in patients with myelofibrosis.
Drugs. 2015 Feb;75(3):297-308. doi: 10.1007/s40265-015-0351-8.
引用本文的文献
1
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.
EJHaem. 2025 Mar 21;6(2):e70007. doi: 10.1002/jha2.70007. eCollection 2025 Apr.
2
Cryptococcosis Associated With Biologic Therapy: A Narrative Review.
Open Forum Infect Dis. 2024 Jun 26;11(7):ofae316. doi: 10.1093/ofid/ofae316. eCollection 2024 Jul.
3
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.
J Fungi (Basel). 2024 Mar 31;10(4):264. doi: 10.3390/jof10040264.
4
Integrated Stress Response (ISR) Pathway: Unraveling Its Role in Cellular Senescence.
Int J Mol Sci. 2023 Dec 13;24(24):17423. doi: 10.3390/ijms242417423.
5
Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability.
Front Pharmacol. 2022 Aug 19;13:896167. doi: 10.3389/fphar.2022.896167. eCollection 2022.
6
Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review.
Clin Case Rep. 2022 Feb 20;10(2):e05461. doi: 10.1002/ccr3.5461. eCollection 2022 Feb.
7
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.
J Fungi (Basel). 2021 Dec 10;7(12):1058. doi: 10.3390/jof7121058.
8
Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report.
Afr J Thorac Crit Care Med. 2021 Oct 4;27(3). doi: 10.7196/AJTCCM.2021.v27i3.116. eCollection 2021.
9
Adverse Effects of Immunosuppression: Infections.
Handb Exp Pharmacol. 2022;272:287-314. doi: 10.1007/164_2021_550.
10
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.
Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.
本文引用的文献
1
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.
2
Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.
N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119.
3
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
4
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.
Nat Biotechnol. 2011 Jun 7;29(6):467-8. doi: 10.1038/nbt0611-467.
5
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.
6
Cryptococcal interactions with the host immune system.
Eukaryot Cell. 2010 Jun;9(6):835-46. doi: 10.1128/EC.00039-10. Epub 2010 Apr 9.
Zotero 插件